7.4662

3.11% -0.2438

Kura Oncology Inc (KURA)

Overview News Price History Option Chain Financials Discussions Forecast

Kura Oncology Inc stock is traded at $7.4662, with a volume of 431.23K. It is down -3.11% in the last 24 hours and down -9.45% over the past month. Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Previous Close:

$7.71

Open:

$7.82

24h Volume:

431.23K

Relative Volume:

0.25

Market Cap:

$576.69M

Revenue:

Net Income/Loss:

$-168.09M

P/E Ratio:

-3.4406

EPS:

-2.17

Net Cash Flow:

$-138.01M

1W Performance:

-5.20%

1M Performance:

-9.45%

6M Performance:

-63.04%

1Y Performance:

-65.40%

1-Day Range:

$7.425

$7.89

1-Week Range:

$7.335

$8.025

52-Week Range:

$6.98

$24.17

Kura Oncology Inc Stock (KURA) Company Profile

Name

Kura Oncology Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

(858) 500-8800

Address

12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA

Employee

142

Twitter

@kuraoncology

Next Earnings Date

2025-02-21

Latest SEC Filings

KURA's Discussions on Twitter

Compare KURA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KURA Kura Oncology Inc	7.465	576.69M	0	-168.09M	-138.01M	-2.17
VRTX Vertex Pharmaceuticals Inc	488.51	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.88	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	635.97	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.49	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	113.23	27.34B	3.30B	-501.07M	1.03B	-2.1146

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy
Oct-14-24	Downgrade	Stifel	Buy → Hold
Dec-22-23	Initiated	Mizuho	Buy
Aug-11-23	Initiated	BofA Securities	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
May-17-23	Initiated	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight
Feb-15-22	Initiated	Jefferies	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-07-20	Reiterated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform
May-05-20	Initiated	Barclays	Overweight
Jul-18-19	Initiated	Deutsche Bank	Buy
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy
Oct-13-16	Resumed	Leerink Partners	Outperform
Jan-22-16	Initiated	JMP Securities	Mkt Outperform
Dec-30-15	Initiated	Oppenheimer	Outperform
Dec-16-15	Initiated	Citigroup	Buy

View All

Kura Oncology Inc Stock (KURA) Latest News

04:20 AM

Kura Oncology’s Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns - TipRanks

Mar 02, 2025

Mar 01, 2025

Research Analysts Set Expectations for Kura Oncology Q1 Earnings - MarketBeat

Mar 01, 2025

Equities Analysts Issue Forecasts for Kura Oncology Q1 Earnings - Defense World

Mar 01, 2025

Kura Oncology (NASDAQ:KURA) Stock Rating Upgraded by StockNews.com - Defense World

Mar 01, 2025

Feb 28, 2025

Kura Oncology (NASDAQ:KURA) Upgraded at StockNews.com - MarketBeat

Feb 28, 2025

Kura Oncology (NASDAQ:KURA) Earns Outperform Rating from Wedbush - MarketBeat

Feb 28, 2025

Kura Oncology (NASDAQ:KURA) Earns Buy Rating from HC Wainwright - MarketBeat

Feb 28, 2025

Kura Oncology (NASDAQ:KURA) shareholders have endured a 64% loss from investing in the stock a year ago - Yahoo Finance

Feb 28, 2025

Feb 27, 2025

Kura Oncology’s Positive Earnings Call Highlights Progress and Prospects - TipRanks

Feb 27, 2025

Kura Oncology (NASDAQ:KURA) Releases Earnings Results, Beats Estimates By $0.43 EPS - MarketBeat

Feb 27, 2025

Investor Network: Kura Oncology, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 27, 2025

Kura Oncology’s Promising Path to FDA Approval: Analyst Recommends ‘Buy’ Following Positive Phase II Results and Strategic Advancements - TipRanks

Feb 27, 2025